Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:29:100645.
doi: 10.1016/j.eclinm.2020.100645. Epub 2020 Nov 20.

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19

Ali S Omrani  1 , Sameer A Pathan  2   3   4 , Sarah A Thomas  5 , Tim R E Harris  2   3 , Peter V Coyle  6 , Caroline E Thomas  2 , Isma Qureshi  2 , Zain A Bhutta  2 , Naema Al Mawlawi  6 , Reham Al Kahlout  6 , Ashraf Elmalik  7 , Aftab M Azad  2 , Joanne Daghfal  1 , Mulham Mustafa  1 , Andrew Jeremijenko  1 , Hussam Al Soub  1 , Mohammed Abu Khattab  1 , Muna Al Maslamani  1   8 , Stephen H Thomas  2   3
Affiliations

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19

Ali S Omrani et al. EClinicalMedicine. 2020 Dec.

Abstract

Background: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19.

Methods: Q-PROTECT employed a prospective, placebo-controlled design with blinded randomization to three parallel arms: placebo, oral HC (600 mg daily for one week), or oral HC plus oral AZ (500 mg day one, 250 mg daily on days two through five). At enrollment, non-hospitalized participants had mild or no symptoms and were within a day of Covid-19 positivity by polymerase chain reaction (PCR). After six days, intent-to-treat (ITT) analysis of the primary endpoint of virologic cure was assessed using binomial exact 95% confidence intervals (CIs) and χ2 testing. (ClinicalTrials.gov NCT04349592, trial status closed to new participants.).

Findings: The study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo) between 13 April and 1 August 2020. HC+AZ, HC, and placebo groups had 6 (3·9%), 7 (4·6%), and 9 (5·9%) participants go off study medications before completing the medication course (p = 0·716). Day six PCR results were available for all 152 HC+AZ participants, 149/152 (98·0%) HC participants, and 147/152 (96·7%) placebo participants. Day six ITT analysis found no difference (p = 0·821) in groups' proportions achieving virologic cure: HC+AZ 16/152 (10·5%), HC 19/149 (12·8%), placebo 18/147 (12·2%). Day 14 assessment also showed no association (p = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events.

Interpretation: HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19.

Funding: The study was supported by internal institutional funds of the Hamad Medical Corporation (government health service of the State of Qatar).

Keywords: Azithromycin; Covid-19; Hyodroxychloroquine.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial or personal relationships with other people or organizations that could represent a conflict of interest.

Figures

Fig 1
Fig. 1
Trial profile.
Fig 2
Fig. 2
Primary outcome of virologic cure at day six.
Fig 3
Fig. 3
Secondary outcome of virologic cure at day 14.
See this image and copyright information in PMC

References

    1. Gautret P., Lagier J.C., Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 - PMC - PubMed
    1. Gautret P., Lagier J.C., Parola P. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34 - PMC - PubMed
    1. Molina J.M., Delaugerre C., Goff J.L. Med Mal Infect. 2020 - PMC - PubMed
    1. Ferner R.E., Aronson J.K... Hydroxychloroquine for Covid-19: what do the clinical trials tell us? 2020. https://www.cebm.net/covid-19/hydroxychloroquine-for-covid-19-what-do-th... (accessed 20 April 2020).
    1. Q-PROTECT Research Protocol. 2020. https://www.hamad.qa/EN/Hospitals-and-services/Communicable-Disease-Cent... (accessed 1 August 2020).

Associated data